ASO Therapy for Parkinson's Disease

ASO Therapy for Parkinson's Disease

Introduction

ASO Therapy for Parkinson's Disease

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">ASO Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Description</td>
</tr>
<tr>
<td class="label">RNase H-mediated degradation</td>
<td>ASO-DNA-RNA hybrid recruits RNase H to cleave the mRNA</td>
</tr>
<tr>
<td class="label">Splicing modulation</td>
<td>ASO alters pre-mRNA splicing to reduce toxic isoforms</td>
</tr>
<tr>
<td class="label">Translational blockade</td>
<td>ASO blocks ribosome assembly on mRNA</td>
</tr>
<tr>
<td class="label">RNA interference</td>
<td>siRNA-loaded nanoparticles</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Company</td>
</tr>
<tr>
<td class="label">LRRK2 ASO</td>
<td>Ionis/partner</td>
</tr>
<tr>
<td class="label">GBA ASO</td>
<td>Various</td>
</tr>
<tr>
<td class="label">SNCA splicing modulators</td>
<td>Research labs</td>
</tr>
<tr>
<td class="label">Parkin ASO</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">System</td>
<td>Potential Adverse Events</td>
</tr>
<tr>
<td class="label">Neurological</td>
<td>Headache, back pain, dizziness</td>
</tr>
<tr>
<td class="label">Injection-related</td>
<td>Lumbar puncture syndrome, spinal headache</td>
</tr>
<tr>
<td class="label">Hematological</td>
<td>Platelet changes, liver enzyme elevations</td>
</tr>
<tr>
<td class="label">Immunogenic</td>
<td>Immune response to ASO</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">ASO therapy</td>
<td>Reduce SNCA mRNA</td>
</tr>
<tr>
<td class="label">[Immunotherapy](/therapeutics/alpha-synuclein-immunotherapy)</td>
<td>Antibody-mediated clearance</td>
</tr>
<tr>
<td class="label">[Aggregation inhibitors](/therapeutics/alpha-synuclein-aggregation-inhibitors)</td>
<td>Prevent fibril formation</td>
</tr>
<tr>
<td class="label">[Gene therapy](/therapeutics/aadc-gene-therapy)</td>
<td>Express therapeutic protein</td>
</tr>
</table>

Antisense oligonucleotide (ASO) therapy for Parkinson's Disease (PD) represents a promising disease-modifying strategy that aims to reduce the expression of [alpha-synuclein](/proteins/alpha-synuclein) (encoded by the [SNCA](/genes/snca) gene), a protein central to PD pathogenesis["@vercruysse2023"]. By targeting the root cause of alpha-synuclein aggregation, ASO therapy offers the potential to slow or halt disease progression rather than merely managing symptoms["@cooper2022"]. This therapeutic approach has garnered significant attention from both academic researchers and pharmaceutical companies, particularly following the success of ASO therapies in other neurological conditions such as spinal muscular atrophy (SMA) and Huntington's disease["@bennett2024"].

Parkinson's disease affects approximately 10 million people worldwide, making it the second most common neurodegenerative disease after Alzheimer's disease["@dorsey2023"]. The characteristic motor symptoms—resting tremor, bradykinesia, rigidity, and postural instability—result from the progressive loss of dopaminergic [neurons](/entities/neurons) in the substantia nigra pars compacta. While symptomatic treatments such as levodopa and deep brain stimulation have improved quality of life for millions of patients, there remains an urgent need for therapies that can modify the underlying disease process["@kalia2015"].

Mechanism of Action

Alpha-Synuclein Reduction Strategy

ASOs for PD are designed to bind to [SNCA](/genes/snca) mRNA transcripts through base-pairing complementarity, preventing their translation into alpha-synuclein protein[@vercruysse2023]. The therapeutic rationale is based on the well-established role of alpha-synuclein in PD pathogenesis:

• Lewy body formation: Alpha-synuclein aggregates are the primary component of Lewy bodies, a hallmark of PD pathology that was first described by Friedrich Lewy in 1912[@spillantini1997]
• Toxic gain-of-function: Misfolded alpha-synuclein exhibits prion-like properties, spreading throughout the nervous system in a manner similar to other protein aggregation diseases[@brundin2017]
• Dopaminergic neuron vulnerability: Alpha-synuclein toxicity particularly affects substantia nigra pars compacta dopamine neurons, leading to the characteristic motor deficits in PD[@dauer2003]

ASO Mechanism Types

ASOs can employ several distinct mechanisms to reduce target gene expression, each with different pharmacological properties[@bennett2024]:

The RNase H-dependent mechanism is the most advanced for SNCA targeting. These ASOs are single-stranded DNA molecules (typically 12-20 nucleotides) that form DNA-RNA hybrids with target mRNA. RNase H recognizes these hybrids and cleaves the RNA strand, leading to mRNA degradation while the ASO is recycled for additional binding events[@bennett2024].

Pharmacodynamic Considerations

The goal of ASO therapy for PD is to achieve partial rather than complete SNCA knock-down[@cooper2022]:

• Therapeutic window: Complete elimination of alpha-synuclein may be detrimental, as the protein has normal physiological functions in synaptic vesicle regulation, neurotransmitter release, and neuronal plasticity[@burre2015]
• Target reduction: Preclinical studies suggest 30-50% reduction may be sufficient to slow disease progression while maintaining sufficient alpha-synuclein for normal neuronal function[@cooper2022]
• CSF biomarkers: Phosphorylated alpha-synuclein (pSer129) and total alpha-synuclein in cerebrospinal fluid serve as pharmacodynamic markers to monitor target engagement[@mollenhauer2023]

Clinical Development

Ionis/Biogen Program: IONIS-SNAS (BIIB101)

The lead ASO program for PD was developed by Ionis Pharmaceuticals in collaboration with Biogen under the name IONIS-SNAS, later designated BIIB101[@biogen2022]:

Development Timeline

• Preclinical phase (2015-2019): Demonstrated dose-dependent SNCA reduction in rodent and non-human primate models, establishing proof-of-concept for CNS delivery[@mcgrew2020]
• Phase 1 (2019-2020): First-in-human study to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers
• Phase 1b/2a (2020-2022): Dose-escalation study in patients with Parkinson's disease to assess safety and preliminary efficacy[@biogen2022]

Trial Design

• Route: Intrathecal (lumbar puncture) administration
• Dosing: Multiple ascending doses, with patients receiving multiple injections over several months
• Endpoints: Safety, tolerability, CSF SNCA protein levels, pharmacokinetics, and exploratory clinical endpoints[@biogen2022]

Trial Outcomes

The Phase 1/2 study showed that BIIB101 was generally well-tolerated with no major safety concerns[@biogen2022]. Common adverse events included headache and mild injection-site reactions, consistent with other intrathecal ASO programs. However, Biogen discontinued the program in 2023 after determining it did not meet criteria for advancement to later-stage trials. The decision was reportedly based on insufficient target engagement or efficacy signals observed in the clinical trial data[@biogen2023].

The discontinuation highlighted several key challenges in ASO development for PD:

Other ASO Programs

Following the Biogen decision, several other ASO programs targeting PD-relevant genes remain in various stages of development[@bennett2024]:

LRRK2 ASO: Gain-of-function mutations in LRRK2 are the most common genetic cause of familial PD, accounting for 5-10% of cases. ASO therapy targeting LRRK2 mRNA could benefit both familial and sporadic PD patients by reducing kinase activity that contributes to neuronal dysfunction[@alessi2018].

GBA ASO: Heterozygous mutations in GBA (glucocerebrosidase) are the most significant genetic risk factor for PD, increasing risk by approximately 5-fold. ASOs targeting GBA could reduce the production of abnormal glucocerebrosidase that leads to alpha-synuclein accumulation in lysosomes[@sidransky2009].

Lessons Learned

The discontinuation of the Biogen program provided valuable insights for future ASO development[@biogen2023]:

Delivery Methods

Intrathecal Administration

The current standard for CNS-targeted ASOs involves intrathecal administration via lumbar puncture[@bennett2024]:

• Procedure: Injection of ASO into cerebrospinal fluid in the lumbar region
• Distribution: Diffuses through CSF to reach spinal cord and some brain regions, with concentrations decreasing with distance from injection site
• Limitations: Invasive procedure requiring repeated lumbar punctures; uneven brain distribution; risk of infection or spinal headache
• Frequency: Typically monthly or quarterly dosing, depending on ASO pharmacokinetics

Emerging Delivery Strategies

New delivery technologies are being developed to overcome the limitations of intrathecal administration[@hammond2021]:

Conjugate Approaches

• Antibody-ASO conjugates: Engineer ASOs to cross the [blood-brain barrier](/entities/blood-brain-barrier) via receptor-mediated transcytosis, using antibodies against transferrin receptor or other BBB-crossing targets
• Cell-penetrating peptides (CPPs): Enhance cellular uptake and endosomal escape through incorporation of peptide sequences derived from HIV TAT protein or other transduction domains
• Aptamer-mediated delivery: Select aptamers that bind to specific receptors on brain endothelial cells to enable receptor-mediated transport

Alternative Routes

• Intravenous with BBB-crossing technology: If successful, would greatly improve patient convenience and enable chronic dosing
• Intranasal delivery: Direct nose-to-brain route under investigation, potentially offering rapid onset with minimal systemic exposure
• Focused ultrasound: Temporary BBB opening using focused ultrasound waves to enhance ASO penetration into specific brain regions[@burgess2024]

Safety Considerations

Adverse Events Profile

Based on the Ionis/Biogen trial and other CNS ASO programs, the safety profile is generally favorable[@biogen2022]:

The safety data from other CNS ASO programs (nusinersen, tofersen, inotersen) suggest that long-term treatment is generally well-tolerated, with most adverse events being mild to moderate in severity[@bennett2024].

Long-term Safety Concerns

Several theoretical long-term safety concerns require ongoing monitoring[@chi2023]:

• Off-target effects: ASOs may bind to unintended mRNA sequences with partial complementarity, potentially leading to unintended gene silencing
• Accumulation: Repeated dosing may lead to tissue accumulation in the CNS or peripheral organs
• CNS inflammation: Potential for neuroinflammation with chronic dosing, though clinical data to date have not shown significant inflammatory responses
• SNCA reduction safety: The long-term effects of sustained partial alpha-synuclein depletion are unknown; animal studies suggest tolerance but human data are limited

Risk Mitigation Strategies

Pharmaceutical companies employ multiple strategies to enhance ASO safety[@bennett2024]:

Current Status and Future Outlook

2025-2026 Landscape

Following the discontinuation of the Biogen program, ASO therapy for PD remains in earlier developmental stages but continues to generate significant research interest[@biogen2023]:

• Academic research: Active investigation of next-generation ASO designs, including allele-selective oligonucleotides and modified chemistries
• Alternative targets: LRRK2, GBA, and other genetic targets remain of interest, with some programs advancing toward clinical development
• Combination approaches: ASO therapy combined with other disease-modifying strategies such as immunotherapy or aggregation inhibitors

Challenges and Opportunities

Key Challenges

Opportunities

Comparison with Other Disease-Modifying Approaches

Conclusion

ASO therapy for Parkinson's Disease represents a scientifically rational approach to disease modification by directly targeting the production of toxic alpha-synuclein. While the Ionis/Biogen program demonstrated the feasibility of ASO delivery to the CNS and established a safety database, the discontinuation of this program highlights the significant challenges remaining in this field[@biogen2023].

The path forward requires addressing several critical gaps:

• Improved delivery technologies that achieve robust brain distribution, particularly to deep brain structures
• Validated biomarkers that accurately reflect target engagement and predict clinical outcomes
• Careful patient selection to identify those most likely to benefit from therapy
• Combination approaches that address multiple aspects of PD pathogenesis

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References